Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PD-1 antibody + mFOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
anti-PD-1 antibody + mFOLFIRINOX is a combination chemo-immunotherapy regimen being evaluated for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The regimen combines an anti-Programmed Cell Death Protein 1 (PD-1) monoclonal antibody, which serves as an immune checkpoint inhibitor to enhance T-cell activity against tumor cells, with the modified FOLFIRINOX (mFOLFIRINOX) chemotherapy backbone. mFOLFIRINOX consists of oxaliplatin (a DNA alkylating agent), irinotecan (a topoisomerase I inhibitor), and 5-fluorouracil (a thymidylate synthase inhibitor) modulated by leucovorin. This combination is primarily being developed and studied by Zhejiang University in randomized clinical trials to determine if the addition of immunotherapy can improve the poor prognosis associated with metastatic pancreatic cancer compared to standard-of-care chemotherapy alone.
- Other names
- Anti-PD-1 Antibody plus mFOLFIRINOXAnti-PD1 Antibody plus mFOLFIRINOXAnti-PD 1 Antibody plus mFOLFIRINOXmFOLFIRINOX + Anti-PD-1 antibody
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on anti-PD-1 antibody + mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PD-1 antibody + mFOLFIRINOX.